ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
1 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
25
|
6.1K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
114K |
7 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
507
|
114K
|
7
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
1 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.1K
|
1
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
3 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.1K
|
3
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
1 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.1K
|
1
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
7 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.1K
|
7
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
6 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.1K
|
6
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
4 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.1K
|
4
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.1K |
4 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.1K
|
4
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
13K |
2 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
48
|
13K
|
2
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
33K |
1 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
62
|
33K
|
1
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
33K |
0 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
62
|
33K
|
0
|
|
ASX - By Stock
|
SVL |
Re:
Ann: Bowdens Silver Successfully Defends Judicial Proceedings
|
|
Eqz
|
105 |
61K |
0 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
105
|
61K
|
0
|
|
ASX - By Stock
|
SVL |
Re:
Ann: Bowdens Silver Successfully Defends Judicial Proceedings
|
|
Eqz
|
105 |
61K |
1 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
105
|
61K
|
1
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
13K |
0 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
48
|
13K
|
0
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
13K |
0 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
48
|
13K
|
0
|
|
ASX - By Stock
|
FGR |
Re:
Ann: Pivotal role secured in $3.72m project
|
|
Eqz
|
3 |
2.1K |
3 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
3
|
2.1K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
114K |
1 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
507
|
114K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
114K |
1 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
507
|
114K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
114K |
5 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
507
|
114K
|
5
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
33K |
5 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
62
|
33K
|
5
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO to present at Emerging Growth Conference
|
|
Eqz
|
14 |
3.6K |
0 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
14
|
3.6K
|
0
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
33K |
17 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
62
|
33K
|
17
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
22K |
8 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
66
|
22K
|
8
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
22K |
4 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
22K
|
4
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
22K |
4 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
22K
|
4
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
22K |
6 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
22K
|
6
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
22K |
8 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
22K
|
8
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
22K |
1 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
22K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Corporate Presentation
|
|
Eqz
|
159 |
78K |
137 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
159
|
78K
|
137
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron Travelan record sales globally, Australia and USA
|
|
Eqz
|
23 |
7.0K |
5 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
23
|
7.0K
|
5
|
|
ASX - By Stock
|
SNS |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
5 |
3.5K |
4 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
5
|
3.5K
|
4
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.5K |
3 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.5K
|
3
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.5K |
3 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.5K
|
3
|
|
Charts
|
SVL |
Re:
SVL chart
|
|
Eqz
|
3.0K |
1.4M |
3 |
12/07/24 |
12/07/24 |
Charts
|
3.0K
|
1.4M
|
3
|
|
Charts
|
SVL |
Re:
SVL chart
|
|
Eqz
|
3.0K |
1.4M |
1 |
12/07/24 |
12/07/24 |
Charts
|
3.0K
|
1.4M
|
1
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.5K |
1 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.5K
|
1
|
|
ASX - By Stock
|
EZZ |
Re:
A particular case
|
|
Eqz
|
43 |
15K |
4 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
43
|
15K
|
4
|
|
ASX - By Stock
|
EZZ |
Re:
A particular case
|
|
Eqz
|
43 |
15K |
2 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
43
|
15K
|
2
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.5K |
3 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.5K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Regulatory Approval to Commence Sales for Striate in Canada
|
|
Eqz
|
23 |
7.5K |
15 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
23
|
7.5K
|
15
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.5K |
3 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
24
|
5.5K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Regulatory Approval to Commence Sales for Striate in Canada
|
|
Eqz
|
23 |
7.5K |
21 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
23
|
7.5K
|
21
|
|
Charts
|
SVL |
Re:
SVL chart
|
|
Eqz
|
3.0K |
1.4M |
2 |
10/07/24 |
10/07/24 |
Charts
|
3.0K
|
1.4M
|
2
|
|
ASX - By Stock
|
EZZ |
Re:
A particular case
|
|
Eqz
|
43 |
15K |
4 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
43
|
15K
|
4
|
|
ASX - By Stock
|
EYE |
Re:
Ann: Record Sales Results
|
|
Eqz
|
131 |
29K |
9 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
131
|
29K
|
9
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Record Quarterly and Yearly Revenue Show Outstanding Growth
|
|
Eqz
|
34 |
8.2K |
8 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
34
|
8.2K
|
8
|
|
ASX - By Stock
|
EYE |
Re:
POTENTIAL RE-RATE CATALYST EVENT: RESULTS
|
|
Eqz
|
124 |
34K |
9 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
124
|
34K
|
9
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron lodges Form F-3 and ATM Prospectus with U.S. SEC
|
|
Eqz
|
9 |
1.8K |
2 |
03/07/24 |
03/07/24 |
ASX - By Stock
|
9
|
1.8K
|
2
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron lodges Form F-3 and ATM Prospectus with U.S. SEC
|
|
Eqz
|
9 |
1.8K |
0 |
03/07/24 |
03/07/24 |
ASX - By Stock
|
9
|
1.8K
|
0
|
|